Systematic review of clinical guidelines for lipid-lowering in the secondary prevention of cardiovascular disease events

Brown, R., Welsh, P. and Logue, J. (2020) Systematic review of clinical guidelines for lipid-lowering in the secondary prevention of cardiovascular disease events. Open Heart, 7(2), e001396. (doi: 10.1136/openhrt-2020-001396) (PMID:33443127) (PMCID:PMC7751215)

[img] Text
225753.pdf - Published Version
Available under License Creative Commons Attribution.



Background: The WHO recommends that those with established cardiovascular disease should be treated with lipid-lowering therapy, but there is no specific guidance regarding lipid monitoring. Unnecessary general practitioner visits may be a burden for patients and increase healthcare costs. A systematic review of the current guidelines was performed to reveal gaps in the evidence base for optimal lipid monitoring approaches. Methods: For this systematic review, a search of Medline, Cumulative Index to Nursing and Allied Health Literature and Turning Research Into Practice databases was conducted for relevant guidelines published in the 10 years prior to 31 December 2019. Recommendations surrounding the frequency of testing, lipid-lowering therapies and target cholesterol values were compared qualitatively. Each guideline was assessed using the 2009 Appraisal of Guidelines for Research and Evaluation II tool. Results: Twenty-two guidelines were included. All recommended statins as the primary lipid-lowering therapy, with a high level of supporting evidence. Considerable variation was found in the recommendations for cholesterol targets. Seventeen guidelines provided at least one cholesterol target, which for low-density lipoprotein (LDL) cholesterol ranged between 1.0 and 2.6 mmol/L, although the most frequently recommended was <1.8 mmol/L (n=12). For long-term follow-up, many recommended reviewing patients annually (n=9), although there was some variation in recommendations for the interval of between 3 and 12 months. Supporting evidence for any approach was limited, often being derived from clinical opinion. Conclusions: Further research is required to provide an evidence base for optimal lipid monitoring of the on-statin secondary prevention population.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Brown, Miss Rosemary and Welsh, Dr Paul and Logue, Dr Jennifer
Authors: Brown, R., Welsh, P., and Logue, J.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Open Heart
Publisher:BMJ Publishing Group
ISSN (Online):2053-3624
Published Online:18 December 2020
Copyright Holders:Copyright © 2020 The Authors
First Published:First published in Open Heart 7(2):e001396
Publisher Policy:Reproduced under a Creative Commons licence

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
304005MRC Precision Medicine Training GrantMorven BarlassMedical Research Council (MRC)MR/N013166/1-LGH/MS/MED25CAMS - Cardiovascular Science